DelveInsight’s ‘Intratumoral Cancer Therapies - Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The Intratumoral Cancer Therapies market report provides emerging drugs, Intratumoral Cancer Therapies market share of the individual cancer types, current and forecasted Intratumoral Cancer Therapies market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Intratumoral Cancer Therapies market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
Study Period: 2018–2030
Intratumoral Cancer Therapies Overview
Over the years, the research and development in cancer have drastically increased, and patients now have several treatment options, which mainly includes chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, stem cell transplant, surgery, and targeted therapy. However, there is still a segment of the cancer patient population who cannot achieve any benefit or improvement from these therapeutic options. These patients face several challenges, including the development of resistance against these therapies. While the research and development for developing treatment options to mitigate prevailing limitations are still undergoing, researchers and industries have developed a keen interest in Intratumoral therapies. Intratumoral (intralesional) administration of immunotherapeutics is a promising way to target local tumor immunity barriers directly. Even though intratumoral therapy most often refers to direct injection into the tumors, it can also refer to any therapy provided in close anatomical proximity to a tumor with the goal of direct uptake by tumors. There are different categories of intratumoral therapies: cytokines, pathogen-associated molecular patterns (PAMPs), oncolytic viruses, cancer gene therapy, monoclonal antibodies, and small molecules.
Currently, only three intratumoral therapies are approved; Imlygic (Talimogene laherparepvec/T-VEC; Amgen), the first oncolytic virus that was approved by the US FDA for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery in 2015. Later, in April 2020, the EU granted approval (CE mark) to Hensify (NBTXR3; Nanobiotix) for the treatment of locally advanced soft tissue sarcoma (STS), however it is not launched yet. Recently, in June 2021, Delytact (teserpaturev/G47∆; Daiichi Sankyo) received conditional and time-limited approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with malignant glioma. The emerging pipeline is majorly focused on the treatment of melanoma, head and neck cancer, Nonmelanoma skin cancer, along with some other cancers and expectations are high from Intratumoral Cancer Therapies.
The Intratumoral Cancer Therapies epidemiology division provides the insights about historical and current Intratumoral Cancer Therapies patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Intratumoral Cancer Therapies epidemiology [segmented as Total Incident cases of selected cancer types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma), Target patient Pool of Intratumoral therapies by Cancer Types and Treated cases by Cancer Types] scenario of Intratumoral Cancer Therapies in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2030.
Drug chapter segment of the Intratumoral Cancer Therapies report encloses the detailed analysis of Intratumoral Cancer Therapies marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Intratumoral Cancer Therapies clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Intratumoral Cancer Therapies Approved Drugs
Delytact (teserpaturev/G47∆/ DS-1647): Daiichi Sankyo
Recently, approved in June 2021, Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1). It has triple mutation within the viral genome that cause augmented and selective replication in cancer cells and enhanced induction of antitumor immune response while retaining high safety features. Delytact has received conditional and time-limited approval in Japan for the treatment of patients with malignant gliomas based on the Phase II study results. Delytact is not approved for any use outside of Japan. Beyond glioblastoma, the product has also been evaluated in patients with castration-resistant prostate cancer, as part of a single-arm, phase I trial (UMIN000010463).
Imlygic (Talimogene laherparepvec; T-VEC): Amgen
Imlygic is a genetically modified herpes simplex virus type 1 designed to replicate within tumors and produce an immunostimulatory protein called granulocyte-macrophage colony-stimulating factor (GM-CSF). Imlygic causes cell lysis, or death, which ruptures tumors, releasing tumor-derived antigens, which along with GM-CSF, may promote an anti-tumor immune response. However, the exact mechanism of action is unknown. In 2015, the drug was approved both in the US as well as in Europe for the treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery.
Hensify (NBTXR3/ PEP503): Nanobiotix
Hensify, the commercial name of NBTXR3, is an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into a tumor prior to a patient’s first standard radiotherapy treatment. After getting exposed to ionizing radiation, the drug intensifies the localized, intratumor killing effect of that radiation. In April 2020, the drug obtained a European market approval (CE mark) enabling commercialization for the treatment of locally advanced soft tissue sarcoma (STS), however this drug has not been launched yet. The company have started with post registrational study of Hensify (Study 401). The trial involves 100 participants and the company aims to launch Hensify in the second half of 2021.
Note: Detailed Current therapies assessment will be provided in the full report of Intratumoral Cancer Therapies
Intratumoral Cancer Therapies Emerging Drugs
Vidutolimod (CMP-001): Checkmate Pharmaceuticals
Vidutolimod (CMP-001) comprises a virus-like particle utilizing a CpG-A oligonucleotide. The company designed it to trigger the body’s innate immune system via TLR9 and infiltrate the tumor microenvironment by the subsequent induction of both innate and adaptive antitumor immune responses. Currently, the company is conducting multiple trials for this drug in indications like neoadjuvant melanoma, CMP-001 as first-line for melanoma, head and neck cancer, and nonmelanoma skin cancers.
Tavokinogene telseplasmid (Tavo): OncoSec Medical Incorporated
Tavo (tavokinogene telseplasmid) is a DNA-based interleukin-12 (IL-12), a naturally occurring protein body with immune-stimulating functions. TAVO is administered directly into the tumor using the company’s proprietary electroporation (EP) gene delivery system, which employs a series of momentary energy pulses. Those pulses are designed to increase the permeability of the cell membrane and facilitate the uptake of IL-12 coded DNA into cells. The drug is being studied in multiple clinical trials, including a registration-directed pivotal Phase II trial (NCT03132675) in metastatic melanoma and other Phase II trials in triple-negative breast cancer, regionally advanced melanoma, and head and neck cancer.
RP1 (Vusolimogene Oderparepvec): Replimune
RP1 is a next-generation oncolytic immunotherapy being developed for indications such as melanoma, cutaneous squamous cell carcinoma, NMSC, and MSI-H. RP1 is a genetically modified HSV-1 designed to destroy tumors directly and generate an antitumor immune response. It is based on a proprietary new strain of the HSV engineered to maximize tumor-killing potency, the immunogenicity of tumor cell death, and the activation of a systemic antitumor immune response. CERPASS (Registration-directed clinical trial) and IGNYTE are Phase II trials and ARTACUS is an ongoing Phase I trial.
INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
INT230-6 is a formulation consisting of the company’s proprietary amphiphilic cell penetration enhancer molecule, 8-([2-hydroxybenzoyl] amino) octanoate, also referred to as SHAO, combined with cisplatin and vinblastine. The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. Currently, this drug is undergoing a Phase I/II (NCT03058289) clinical trial for soft-tissue sarcoma. In April 2020, the US FDA granted Fast Track designation to INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer who have failed at least two prior lines of therapy.
NanoPac (LSAM Paclitaxel): NanOlogy
NanoPac is made up of tiny particles of another drug called paclitaxel, a chemotherapy drug approved by the US FDA for other types of cancer. NanoPac microparticles are designed for local administration and become entrapped in the tumor, allowing for sustained therapeutic drug release. Currently, NanoPac is being studied in an ongoing Phase II (NCT03077685) trial for locally advanced pancreatic adenocarcinoma. In November 2020, NanOlogy enrolled the first patient in a Phase II (NCT04221828) trial of NanoPac for local prostate cancer but due to lack of enrollment, this trial has been terminated.
LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB
LOAd703 is an immunostimulatory oncolytic virus, based on company’s proprietary LOAd technology, used in a family of armed oncolytic viruses that can activate the body’s immune system to identify, seek out, and destroy cancer cells. LOAd703 is in the initial phase of clinical development and being evaluated in multiple Phase I/II trials. In 2015, the US FDA and EMA granted Lokon Pharma an Orphan Drug designation for LOAd703 immunotherapy to treat pancreatic cancer, and the ongoing trial (NCT02705196) assessing the drug to treat this cancer is expected to get completed by December 2021.
Intuvax (Ilixadencel): Immunicum AB
Intuvax uses dendritic cells sourced from healthy human donors that are specifically activated to produce significant amounts of vigorous immune stimulatory factors. By intratumoral administration, these cells induce a local inflammatory reaction, leading to the destruction of tumor cells and recruitment and activation of the patient’s dendritic cells into the tumor environment. It is currently being evaluated in the Phase Ib/II (NCT03735290) study in combination with checkpoint inhibitors in patients with advanced cancer who are candidates for CPI Therapy.
Note: Detailed emerging therapies assessment will be provided in the final report.
Key Findings
The Intratumoral Cancer Therapies market size in the 7MM is expected to change during the forecast period 2021–2030. According to the estimates, the highest market size of Intratumoral Cancer Therapies is found in the United States.
The United States Market Outlook
In United States, the total market size of Intratumoral Cancer Therapies is expected to increase at a CAGR of 42.0% during the study period (2018–2030).
EU-5 Countries: Market Outlook
In the EU-5 countries, the total market size of Intratumoral Cancer Therapies is expected to increase at a CAGR of 44.4% during the study period (2018–2030).
The drugs which are in pipeline include:
And others…..
Note: Detailed emerging therapies assessment will be provided in the final report.
Analysts Insight
Imlygic from Amgen, is the first and only the FDA approved viral therapy that is injected directly into melanoma tumors. Despite the initial hype for this exciting intratumoral mode of cancer gene therapy, Imlygic’s debut did not translate into much commercial success in the melanoma market. Limitations of the intratumoral administration, no statistically significant benefit in overall survival and the intense competition from immune checkpoint inhibitors due to their efficacy and manageable side effects are some of the main factors for insignificant revenues of this novel therapy. Currently, the pipeline for Intratumoral Cancer Therapies is very rich with potential candidates of various drug classes. Most of the emerging therapies are working on the principle of turning ""cold"" tumors to ""hot"" and then simultaneously targeting the tumor with immune checkpoint inhibitors. DelveInsight’s analysts have also accessed that Melanoma will dominate the Intratumoral therapeutic landscape when it comes to the nine cancer indications that are chosen for market assessment of Intratumoral therapies.
To keep up with current market trends, we take KOLs and SME’s opinion working in Intratumoral Cancer Therapies domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Intratumoral Cancer Therapies market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Intratumoral Cancer Therapies Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario and Emerging Therapies:
1. Key Insights
2. Report Introduction
3. Intratumoral cancer therapies Market Overview at a Glance
3.1. Market Share (%) Distribution of Intratumoral cancer therapies in 2018: By Country
3.2. Market Share (%) Distribution of Intratumoral cancer therapies in 2030: By Country
3.3. Market Share (%) Distribution of Intratumoral cancer therapies in 2025: By Indication
3.4. Market Share (%) Distribution of Intratumoral cancer therapies in 2030: By Indication
4. Key Highlights from Report
5. Executive Summary of Intratumoral cancer therapy
5.1. Key Events
6. Epidemiology and Market Forecast Flow
7. Background and Overview
7.1. Introduction
7.2. Cancer Therapy
7.3. Intratumoral Therapies
7.4. History of Intratumoral Therapies
7.5. Mechanism of Intratumoral Therapies
7.6. Principles of Intratumoral Immunotherapy
7.6.1. In Situ Priming of Antitumor Immunity
7.6.2. Use the Tumor as its Own Vaccine
7.6.3. Avoid Systemic Toxicities
7.7. Tumor Properties to Consider for Intratumoral Therapies
7.7.1. Tumor Microenvironment
7.7.2. Intratumoral Transport
7.8. Categories of Intratumoral Therapies
7.8.1. Pathogen-associated Molecular Patterns (PAMPs)
7.8.2. Cytokines
7.8.3. Oncolytic Viruses
7.8.4. Cancer Gene Therapy
7.8.5. Monoclonal Antibodies
7.8.6. Small Molecules
7.9. Advantages of Intratumoral Therapies
7.10. Limitations of Intratumoral Therapies
7.10.1. Emerging Therapies and Future Directions
8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario
8.3.1. Total Incident cases of selected cancer types across the 7MM
8.3.2. Target Patient Pool of Intratumoral therapies by Cancer Types across the 7MM
8.3.3. Treated cases by Cancer Types across the 7MM
9. Key Endpoints in Intratumoral cancer therapies
10. Marketed Therapies
10.1. Key Cross of Marketed Therapies
10.2. Delytact (teserpaturev/G47∆/ DS-1647): Daiichi Sankyo
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Pivotal Clinical Trial
10.3. Imlygic (Talimogene laherparepvec; T-VEC): Amgen
10.3.1. Product Description
10.3.2. Regulatory Milestones
10.3.3. Other Developmental Activities
10.3.4. Pivotal Clinical Trial
10.3.5. Ongoing Current Pipeline Activity
10.3.6. Safety and Efficacy
11. Emerging Therapies
11.1. Key Cross of Emerging Therapies
11.2. Tilsotolimod (IMO-2125): Idera Pharmaceuticals
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.3. Nidlegy (Daromun; L19IL2 + L19TNF): Philogen
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.4. Telomelysin (OBP-301; Suratadenoturev): Oncolys BioPharma
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.4. Safety and Efficacy
11.5. BO-112: Highlight Therapeutics
11.5.1. Product Description
11.5.2. Other Developmental Activities
11.5.3. Clinical Development
11.5.4. Safety and Efficacy
11.6. MTG201 (Ad5-SGE-REIC/Dkk-3): Momotaro-Gene
11.6.1. Product Description
11.6.2. Other Developmental Activities
11.6.3. Clinical Development
11.7. Controlled IL-12 (Ad-RTS-hIL-12 + Veledimex; INXN2001): Ziopharm
11.7.1. Product Description
11.7.2. Other Developmental Activities
11.7.3. Clinical Development
11.7.4. Safety and Efficacy
11.8. Canerpaturev (C-REV; HF-10; TBI-1401): Takara Bio
11.8.1. Product Description
11.8.2. Other Developmental Activities
11.8.3. Clinical Development
11.8.4. Safety and Efficacy
11.9. NanoPac (LSAM Paclitaxel): NanOlogy
11.9.1. Product Description
11.9.2. Other Developmental Activities
11.9.3. Clinical Development
11.9.4. Safety and Efficacy
11.10. Pexa-Vec (Pexastimogene Devacirepvec; JX-594): SillaJen
11.10.1. Product Description
11.10.2. Other Developmental Activities
11.10.3. Clinical Development
11.10.4. Safety and Efficacy
11.11. HB-201: Hookipa Biotech GmbH
11.11.1. Product Description
11.11.2. Other Developmental Activities
11.11.3. Clinical Development
11.11.4. Safety and Efficacy
11.12. LOAd703: Lokon Pharma AB
11.12.1. Product Description
11.12.2. Other Developmental Activities
11.12.3. Clinical Development
11.12.4. Safety and Efficacy
11.13. Vidutolimod (CMP-001): Checkmate Pharmaceuticals
11.13.1. Product Description
11.13.2. Other Developmental Activities
11.13.3. Clinical Development
11.13.4. Safety and Efficacy
11.14. PVSRIPO: Istari Oncology
11.14.1. Product Description
11.14.2. Other Developmental Activities
11.14.3. Clinical Development
11.14.4. Safety and Efficacy
11.15. Voyager-V1 (VV1/ VSV-IFNβ-NIS): Vyriad
11.15.1. Product Description
11.15.2. Other Developmental Activities
11.15.3. Clinical Development
11.15.4. Safety and Efficacy
11.16. MK-1454: Merck Sharp & Dohme Corp.
11.16.1. Product Description
11.16.2. Clinical Development
11.16.3. Safety and Efficacy
11.17. Tavokinogene telseplasmid (Tavo): OncoSec Medical Incorporated
11.17.1. Product Description
11.17.2. Other Developmental Activities
11.17.3. Clinical Development
11.17.4. Safety and Efficacy
11.18. AIV001: AiViva Biopharma
11.18.1. Product Description
11.18.2. Clinical Development
11.19. Intuvax (Ilixadencel): Immunicum AB
11.19.1. Product Description
11.19.2. Other Developmental Activities
11.19.3. Clinical Development
11.19.4. Safety and Efficacy
11.20. Cavrotolimod (AST-008): Exicure
11.20.1. Product Description
11.20.2. Other Developmental Activities
11.20.3. Clinical Development
11.20.4. Safety and Efficacy
11.21. AlloStim: Immunovative Therapies
11.21.1. Product Description
11.21.2. Other Developmental Activities
11.21.3. Clinical Development
11.21.4. Safety and Efficacy
11.22. PV-10: Provectus Biopharmaceuticals
11.22.1. Product Description
11.22.2. Other Developmental Activities
11.22.3. Clinical Development
11.22.4. Safety and Efficacy
11.23. Cotsiranib (STP705): Sirnaomics
11.23.1. Product Description
11.23.2. Other Developmental Activities
11.23.3. Clinical Development
11.23.4. Safety and Efficacy
11.24. Sotigalimab (APX005M): Apexigen
11.24.1. Product Description
11.24.2. Other Developmental Activities
11.24.3. Clinical Development
11.25. RP1 (Vusolimogene Oderparepvec): Replimune
11.25.1. Product Description
11.25.2. Other Developmental Activities
11.25.3. Clinical Development
11.25.4. Safety and Efficacy
11.26. V937 (CVA21/CAVATAK): Merck & Co (Viralytics)
11.26.1. Product Description
11.26.2. Other Developmental Activities
11.26.3. Clinical Development
11.26.4. Safety and Efficacy
11.27. mRNA-2416: Moderna Therapeutics
11.27.1. Product Description
11.27.2. Clinical Development
11.27.3. Safety and Efficacy
11.28. INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
11.28.1. Product Description
11.28.2. Other Developmental Activities
11.28.3. Clinical Development
11.28.4. Safety and Efficacy
11.29. DNX-2401 (Tasadenoturev): DNAtrix
11.29.1. Product Description
11.29.2. Other Developmental Activities
11.29.3. Clinical Development
11.29.4. Safety and Efficacy
11.30. G207: Treovir
11.30.1. Product Description
11.30.2. Other Developmental Activities
11.30.3. Clinical Development
11.30.4. Safety and Efficacy
11.31. Hensify (NBTXR3/ PEP503): Nanobiotix
11.31.1. Product Description
11.31.2. Other Developmental Activities
11.31.3. Clinical Development
11.31.4. Safety and Efficacy
12. Intratumoral Cancer Therapies: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Outlook
12.3. Market Size of Intratumoral Cancer Therapies
12.3.1. Total Market Size of Intratumoral Cancer Therapies
12.3.2. Total Market Size of Intratumoral Cancer Therapies by Indications
12.3.3. Market Size of Intratumoral Cancer Therapies by Therapies
13. Market Access and Reimbursement
13.1. NICE UK
13.2. IQWiG And GBA Assessment
13.3. Japan
13.4. Patient Assistance Programs
13.5. Future Therapy Assessment
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List of Table
Table 1: Summary of Intratumoral Cancer Therapy: Market, Epidemiology, and Key Events (2018–2030)
Table 2: Factors Affecting Transport of Therapy Out of the Tumor After Intratumoral Injection and Probable Transport Phenomena
Table 3: Categories of intratumoral therapies to treat cancer
Table 4: Intratumoral Immunotherapy: Universal Rather Than Personalized Cancer Immunization
Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates
Table 6: Total Incident cases of selected cancer types across the 7MM (in Thousands) (2018–2030)
Table 7: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM (in Thousands) (2018–2030)
Table 8: Treated cases by Cancer Types across the 7MM (2018–2030)
Table 9: Recommended Dose and Schedule for Imlygic
Table 10: Imlygic (Talimogene laherparepvec), Clinical Trial Description, 2021
Table 11: Tilsotolimod (IMO-2125); Clinical Trial Description, 2021
Table 12: Nidlegy (Daromun; L19IL2 + L19TNF), Clinical Trial Description, 2021
Table 13: Telomelysin (OBP-301; Suratadenoturev), Clinical Trial Description, 2021
Table 14: BO-112, Clinical Trial Description, 2021
Table 15: MTG201 (Ad5-SGE-REIC/Dkk-3), Clinical Trial Description, 2021
Table 16: Controlled IL-12 (Ad-RTS-hIL-12 + Veledimex; INXN2001), Clinical Trial Description, 2021
Table 17: Canerpaturev (C-REV; HF-10; TBI-1401), Clinical Trial Description, 2021
Table 18: NanoPac (LSAM Paclitaxel; Paclitaxel nanoformulation), Clinical Trial Description, 2021
Table 19: Pexa-Vec (Pexastimogene Devacirepvec; JX-594), Clinical Trial Description, 2021
Table 20: HB-201, Clinical Trial Description, 2021
Table 21: LOAd703, Clinical Trial Description, 2021
Table 22: Vidutolimod (CMP-001); Clinical Trial Description, 2021
Table 23: PVSRIPO; Clinical Trial Description, 2021
Table 24: Voyager-V1 (VV1); Clinical Trial Description, 2021
Table 25: MK-1454; Clinical Trial Description, 2021
Table 26: Tavokinogene telseplasmid (tavo); Clinical Trial Description, 2021
Table 27: AIV001; Clinical Trial Description, 2021
Table 28: Intuvax (Ilixadencel); Clinical Trial Description, 2021
Table 29: Cavrotolimod (AST-008); Clinical Trial Description, 2021
Table 30: AlloStim; Clinical Trial Description, 2021
Table 31: PV-10; Clinical Trial Description, 2021
Table 32: Cotsiranib (STP705); Clinical Trial Description, 2021
Table 33: Sotigalimab (APX005M); Clinical Trial Description, 2021
Table 34: RP1 (vusolimogene oderparepvec); Clinical Trial Description, 2021
Table 35: V937 (CVA21/CAVATAK), Clinical Trial Description, 2021
Table 36: mRNA-2416, Clinical Trial Description, 2021
Table 37: INT230-6 (Cisplatin/vinblastine), Clinical Trial Description, 2021
Table 38: DNX-2401 (Tasadenoturev), Clinical Trial Description, 2021
Table 39: G207, Clinical Trial Description, 2021
Table 40: Hensify (NBTXR3), Clinical Trial Description, 2021
Table 41: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2018–2030)
Table 42: 7MM Market Size of Intratumoral Cancer Therapies By Indications in USD Million (2018–2030)
Table 43: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2018–2030)
Table 44: The United States Market Size of Intratumoral Cancer Therapies by Therapies in USD Million (2018–2030)
Table 45: EU-5 Market Size of Intratumoral Cancer Therapies by Therapies in USD Million (2018–2030)
Table 46: Japan Market Size of Intratumoral Cancer Therapies by Therapies in USD Million (2018–2030)
Table 47: NICE Assessment for Inratumoral Therapies
List of Figures
Figure 1: Types of Cancer Treatment
Figure 2: Timeline for Intratumoral Immunotherapy
Figure 3: Intratumoral Immunotherapy Mechanisms and Invoking an Abscopal Effect
Figure 4: Principle of Intratumoral Immunotherapy
Figure 5: Classification of the Different Types of Immunotherapy Agents
Figure 6: Global Heat Map of all cancers in 2020, both sexes, all ages
Figure 7: Total Incident cases of selected cancer types across the 7MM in the 7MM (2018–2030)
Figure 8: Target patient Pool of Intratumoral therapies by Cancer Types across the 7MM in the 7MM (2018–2030)
Figure 9: Treated cases by Cancer Types across the 7MM in the 7MM (2018–2030)
Figure 10: Intratumoral immunotherapy clinical trials
Figure 11: Mechanism of action of Telomelysin
Figure 12: Controlled IL-12 platform
Figure 13: Mode of action of C-REV
Figure 14: Tumor tissue concentration of NanoPac and company’s other drug:NanoDoce, versus comparators all given intratumorally in a mouse model
Figure 15: Mode of action of Pexa-Vec
Figure 16: Mechanism of action
Figure 17: Mechanism of action
Figure 18: Structure of DNX-2401 (Tasadenoturev)
Figure 19: Market Size of Intratumoral Cancer Therapies in the 7MM, USD Million (2018–2030)
Figure 20: Market Size of Intratumoral Cancer Therapies By Indications in the 7MM, USD Million (2018–2030)
Figure 21: 7MM Market Size of Intratumoral Cancer Therapies in USD Million (2018–2030)
• Daiichi Sankyo
• Amgen
• Idera Pharmaceuticals
• Philogen
• Oncolys BioPharma
• Highlight Therapeutics
• Momotaro-Gene
• Ziopharm
• Takara Bio
• NanOlogy
• SillaJen
• Hookipa Biotech GmbH
• Lokon Pharma AB
• Checkmate Pharmaceuticals
• Istari Oncology
• Vyriad
• Merck Sharp & Dohme Corp.
• OncoSec Medical Incorporated
• AiViva Biopharma
• Immunicum AB
• Exicure
• Immunovative Therapies
• Provectus Biopharmaceuticals
• Sirnaomics
• Apexigen
• Replimune
• Merck & Co (Viralytics)
• Moderna Therapeutics
• Intensity Therapeutics
• DNAtrix
• Treovir
• Nanobiotix
